knowledge -WSS

knowledge

author：entertainment 2025-08-12 09:08:50 - browse：48214

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Bispecific antibodies are next new thing in cancer immunotherapy

WSS

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Patients, doctors are clashing about side effects of hormonal birth control

SEC charges former device maker CEO with $41 million fraud

Senate panel passes drug pricing bills, but drops one PBM reform

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

What STAT readers think about the FDA and patient advocacy

hotspot

knowledge

hotspot

Sports medicine is finally prioritizing gender equality

Altering the blood type of lungs raises potential for universal organs for transplants

Medicare proposal to cover medical devices draws a mixed reaction

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Cancer drug shortages should be causing more outrage

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Activists slam private health insurers over coverage restrictions

Novo: Oral version of Ozempic leads to 15% weight loss

Walensky prepares to leave CDC — and Congress — behind

FDA approves first new drug developed for postpartum depression

hotspot

Living organ donors deserve priority status for transplants

Living organ donors deserve priority status for transplants

Christmas in the PICU brings some surprising joy

How to fix the rural physician shortage in the U.S.

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Grail spinoff by Illumina should end disastrous merger attempt

hotspot

hotspot

Wikipedia

hotspot